Bank stocks set to do ‘pretty well’ under Trump 2.0, investor says, naming his favorites

Bank stocks set to do ‘pretty well’ under Trump 2.0, investor says, naming his favorites


Wall Street will 'do quite well' against the backdrop of U.S. tariffs: CIO

Investment bank stocks are set to benefit from the Trump presidency, according to investor Kingsley Jones, who said it was time for financials to “step up.”

Speaking to CNBC’s Martin Soong, the Australian investor struck a bullish tone on the outlook for stocks as U.S. President Donald Trump’s second term gets underway.

“Wall Street, in general, will do quite well out of the Trump presidency,” Jones, founder and chief investment officer at advisory firm Jevons Global, said.

He added that banks were particularly well placed, given Trump’s promise to loosen deal-making regulations and imposition of trade tariffs which could see businesses re-focus on the U.S.

“When you have a time of great change like this, which is very pro-business in the United States — a lot of talk about building new factories, plus shifting trade patterns — I think the financials will do pretty well,” Jones said.

“There’s a big need for investment banks to step up and finance whatever activity changes are going to happen,” he added, naming JPMorgan and Goldman Sachs as two stocks he particularly likes.

It comes after a record-breaking quarter for the banks, following bumper trading activity around the presidential election and more investment banking deals.

Trump’s return to the White House is expected to boost investment bank income to $316 billion in 2025, according to data and analytics group Coalition Greenwich, Reuters reported. The same data suggests that M&A bankers could earn around $27.6 billion in fees. If so, it would be the second-highest-grossing year in two decades.

Following Trump’s election victory in November, dealmakers and leaders on Wall Street said they expect the floodgates to open on merger and acquisition activity. Goldman Sachs CEO David Solomon echoed this sentiment in January, claiming that Trump had brought back “a meaningful shift in CEO confidence” and “increased appetite for dealmaking supported by an improving regulatory backdrop.”

Two-horse AI race

Elsewhere, Jones said the emergence of China’s Open AI model DeepSeek is set to spark a “boom” in artificial intelligence competition.

However, he said it’s firmly a two-horse race between the U.S and China.

“There’s going to be a boom in China of applications of these models, and also in the United States and elsewhere,” he said.

“[But] it’s those two nations that lead,” Jones said, adding that Europe is “starting from behind.”

OpenAI exec: DeepSeek reaffirms that there's real competition in AI



Source

Google joins Microsoft in telling users Anthropic is still available outside defense projects
World

Google joins Microsoft in telling users Anthropic is still available outside defense projects

Google CEO Sundar Pichai gestures to the crowd during Google’s annual I/O developers conference in Mountain View, California, on May 20, 2025. David Paul Morris | Bloomberg | Getty Images Google said it will continue offering Anthropic’s artificial intelligence technology for clients, excluding for defense work, a day after Microsoft issued a similar statement to […]

Read More
Market turmoil is hitting most traditional safe havens. UBS says this is the place to hide
World

Market turmoil is hitting most traditional safe havens. UBS says this is the place to hide

The U.S. and Israel are showing signs of escalating their war against Iran – a move that could batter a variety of assets, even traditional safe havens. To protect their portfolios, investors can snap up stocks from an oft-shorted sector: pharmaceuticals, UBS analysts say. Since the first strikes last Saturday, the Iran War has roiled […]

Read More
Zealand’s stock falls 35% after disappointing drug result. Its CEO tells CNBC people need to focus less on the ‘weight loss Olympics’
World

Zealand’s stock falls 35% after disappointing drug result. Its CEO tells CNBC people need to focus less on the ‘weight loss Olympics’

Wegovy is produced by pharmaceutical company Novo Nordisk and has been approved for specifically for chronic weight management in adults and adolescents. (Photo by Steve Christo – Corbis/Corbis via Getty Images) Steve Christo – Corbis | Corbis News | Getty Images The chief executive of drugmaker Zealand Pharma sought to calm investors about the latest […]

Read More